FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME)
FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru
Sponsor: Menzies School of Health Research
This PHASE3 trial investigates Malaria and Plasmodium Vivax Malaria and is currently actively recruiting participants. Menzies School of Health Research leads this study, which shows 15 recorded versions since 2024 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
15 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
▶ Show 10 earlier versions
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE3
-
May 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Menzies School of Health Research
- National Institute of Allergy and Infectious Diseases (NIAID)
- Oxford University Clinical Research Unit Indonesia
- PATH
- Stanford University
- Universidad Peruana Cayetano Heredia- subcontractor to UCSF as local Sponsor
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .